Related Experiment Video
Updated: Jun 29, 2025
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy
Angel Guan1,2, Justin J-L Wong1,2
1Epigenetics and RNA Biology Laboratory, Charles Perkins Centre, University of Sydney, Camperdown, Australia.
Abstract:
The N6-methyladenosine (m6A) RNA modification has gained significant prominence as a new layer of regulatory mechanism that governs gene expression. Over the past decade, various m6A regulators responsible for introducing, eliminating, and recognising RNA methylation have been identified. Notably, these m6A regulators often exhibit altered expression patterns in cancer, occasionally offering prognostic value. Nonetheless, the complex roles of these regulators in human cancer pathology remain enigmatic, with conflicting outcomes reported in different studies.In recent years, a multitude of inhibitors and activators targeting m6A regulators have been reported. Several of these compounds have demonstrated promising efficacy in both in vitro and in vivo cancer models. These findings collectively underscore the dynamic landscape of m6A regulation in cancer biology, revealing its potential as a therapeutic target and prognostic indicator.
Insights
N6-methyladenosine (m6A) RNA modification regulates gene expression and is altered in cancer. Targeting m6A regulators shows promise for cancer therapy and offers prognostic insights.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- N6-methyladenosine (m6A) is a key RNA modification regulating gene expression.
- m6A regulators are increasingly implicated in various human cancers.
- The precise roles of m6A regulators in cancer pathology are complex and often contradictory.
Purpose of the Study:
- To review the current understanding of m6A regulators in cancer.
- To explore the therapeutic potential of targeting m6A regulators.
- To highlight the prognostic value of m6A regulators in cancer.
Main Methods:
- Literature review of studies on m6A RNA modification and cancer.
- Analysis of m6A regulators' expression patterns in cancer.
- Evaluation of therapeutic agents targeting m6A regulators in preclinical models.
Main Results:
- m6A regulators are frequently dysregulated in cancer, impacting gene expression.
- Compounds targeting m6A regulators demonstrate efficacy in vitro and in vivo cancer models.
- Altered expression of m6A regulators can serve as a prognostic biomarker.
Conclusions:
- m6A RNA modification is a critical regulatory layer in cancer biology.
- Targeting m6A regulators represents a promising therapeutic strategy for cancer treatment.
- m6A regulators hold significant potential as prognostic indicators in oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15Experimental RNAi
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:22MicroRNAs